|
answer text |
<p>The updated NHS England clinical commissioning policy establishes the use of generic
and second line pre-exposure prophylaxis (PrEP) for human immunodeficiency virus prevention,
including emtricitabine and tenofovir alafenamide (Descovy®) as a second line treatment
option for individuals who meet the inclusion criteria and cannot take the usual first-line
PrEP therapy due to risk factors.</p><p>The commissioning policy was published on
22 May 2023 and is available at the following link:</p><p><a href="https://www.england.nhs.uk/publication/reimbursement-for-the-use-of-generic-drugs-for-pre-exposure-prophylaxis-prep-for-the-prevention-of-hiv/"
target="_blank">https://www.england.nhs.uk/publication/reimbursement-for-the-use-of-generic-drugs-for-pre-exposure-prophylaxis-prep-for-the-prevention-of-hiv/</a></p>
|
|